Search Results

Ruxolitinib 10 mg  | 99.40%

TargetMol

Ruxolitinib is a potent and selective JAK1/2 inhibitor (IC50: 3.3/2.8 nM) and is relatively less selective for JAK3 (IC50: 322 nM).

More Information Supplier Page

Ruxolitinib 25 mg  | 99.40%

TargetMol

Ruxolitinib is a potent and selective JAK1/2 inhibitor (IC50: 3.3/2.8 nM) and is relatively less selective for JAK3 (IC50: 322 nM).

More Information Supplier Page

Ruxolitinib 5 mg  | 99.40%

TargetMol

Ruxolitinib is a potent and selective JAK1/2 inhibitor (IC50: 3.3/2.8 nM) and is relatively less selective for JAK3 (IC50: 322 nM).

More Information Supplier Page

LY2109761 10 mg  | 99.64%

TargetMol

LY2109761 is a novel selective TGF-β receptor type I/II (TβRI/II) dual inhibitor with Ki of 38 nM and 300 nM, respectively; shown to negatively affect the phosphorylation of Smad2.

More Information Supplier Page

LY2109761 25 mg  | 99.64%

TargetMol

LY2109761 is a novel selective TGF-β receptor type I/II (TβRI/II) dual inhibitor with Ki of 38 nM and 300 nM, respectively; shown to negatively affect the phosphorylation of Smad2.

More Information Supplier Page

LY2109761 50 mg  | 99.64%

TargetMol

LY2109761 is a novel selective TGF-β receptor type I/II (TβRI/II) dual inhibitor with Ki of 38 nM and 300 nM, respectively; shown to negatively affect the phosphorylation of Smad2.

More Information Supplier Page

Valnemulin hydrochloride 50 mg  | 99.83%

TargetMol

Valnemulin hydrochloride (Valnemulin HCl) is a broad-spectrum bacteriostatic agent inhibiting protein synthesis in bacteria by binding to the peptidyl transferase component of the 50S subunit of ribosomes.

More Information Supplier Page